Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status
US-2024094223-A1 · Mar 21, 2024 · US
Methods and biomarkers for the detection of dengue hemorrhagic fever
US9103826B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9103826-B2 |
| Application number | US-201213490360-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 6, 2012 |
| Priority date | Jun 6, 2011 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for differentiating dengue disease severity in an individual having a dengue virus infection, the method comprising: (1)-determining the presence and quantity of or absence of high molecular weight albumin*2, high molecular weight albumin*3, IL-10, fibrinogen, complement 4A (C4A), immunoglobulin, tropomyosin, and albumin*1 in a plasma sample from the individual by (a) contacting a plasma sample from the individual with probes that specifically bind…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
- G01N33/6869Primary
Physics · mapped topic
Physics · mapped topic
- G01N33/564Primary
Physics · mapped topic
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9103826B2 cover?
- The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms o…
- Who is the assignee on this patent?
- Kochel Tadeusz, Nores Garcia Josefina, Brasier Allan, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6869. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).